Vericel’s High Growth Trajectory Has Staying Power

By Mike Evers

Vericel’s High Growth Trajectory Has Staying Power
The company's MACI product drive 35% growth in 2019 and has penetrated just a quarter of Vericel's target addressable market of 5,000 surgeons.

Member-Only Content

SUBSCRIBE Login

Product Labels: PRP/Cell-Based/Osteoinductive Materials

Tags: Revenue Report